July 2026—Tempus AI has launched the ArteraAI Prostate test (mHSPC) for clinical use. The test uses multimodal artificial intelligence to provide insights for personalized care for patients with metastatic hormone-sensitive prostate cancer. It assesses a patient’s clinical information and histopathology biopsy image to produce a personalized risk estimate of the patient’s likelihood of prostate cancer-specific mortality. The CLIA-certified and CAP-accredited test will be integrated into the Tempus platform. Clinicians will be able to order the test as an add-on to Tempus’ solid tumor portfolio.
Webinars and Sponsored Roundtables — Register Now
Thursday, August 20, 2026. 12 PM-1:30 PM ET
Hear from an expert in HER2 IHC whose work has contributed to current scoring guidelines.
Webinar presenter Josef Ruschoff, MD, PhD, Former Chief Medical Officer and Co-Founder of Targos, Senior Consultant of Discovery Life Sciences, Kassel, Germany.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
To be rescheduled to a future date
Learn about digital pathology technology that is future-ready, yet practical for today’s
laboratory needs.
Webinar presenters Scott Hammond, Senior Systems Consultant, Digital Pathology Division, Wexner Medical Center, Department of Pathology, and Ursula Hofer, Imaging Technologist, Pathology Digital Imaging Lab, Wexner Medical Center, Department of Pathology, and Sandra Banky, PA(ASCP), Director of Operations, Wexner Medical Center, Department of Pathology.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY